ERBB2 and breast cancer: Very recently, the FDA approved the aforementioned Sacituzumab Govitecan, which targets Trop2 for metastatic breast cancer therapy, as well as the next generation in HER2-targeting ADCs, Trastuzumab deruxtecan [15–17].